| Literature DB >> 35126603 |
Sian Pan1, Shaohua Wang1, Juan Li1, Hanyu Yuan1, Xiao Xue1, Yu Liu1, Zenghui Yue1.
Abstract
The latest spectrum of moxibustion disease shows that primary dysmenorrhea is a high-frequency symptom of moxibustion and that it is the dominant clinical disease. In the specific treatment methods, all types of moxibustion methods have been widely used, such as thermal, thunder fire, partitioned, and spreading moxibustion. Moxibustion plays a therapeutic role through its four mechanisms of action: heat, light, moxa smoke, and drug effects. The mechanism of moxibustion treatment for primary dysmenorrhea focuses on adjusting endocrine hormones, regulating immune function and neuro-related factors, and improving uterine microcirculation. In this study, based on the clinical evidence of different moxibustion methods for treating primary dysmenorrhea, the design model, intervention characteristics, and clinical outcomes were analyzed. Meanwhile, the brain effect mechanisms of different imaging methods were summarized from the perspective of neuroimaging. It was pointed out that the left anterior cingulate gyrus, left inferior parietal angular gyrus, and left superior gyrus may be the analgesic brain regions that regulate sensory, emotional, and cognitive aspects. Moreover, the neural circuits involved can be inferred: the frontal cortex-basal ganglia (the pea nucleus)-cerebral cortex, which mediates motivation and emotional drive, and the parietal lobe-basal ganglia-limbic lobe-frontal lobe, which is involved in neurotransmitter transport and emotional regulation and behavioral expression. There are still problems and deficiencies in studies on the mechanism of moxibustion treatment for primary dysmenorrhea. Studies should be strengthened on how moxibustion produces an effect. Attention should be paid to exploring how the spectrum range and peak in the light effect of moxibustion treat primary dysmenorrhea. Studies assessing the mechanisms of moxibustion treatment for primary dysmenorrhea should be conducted to provide an experimental basis and evidence-based medical evidence for clinical treatment.Entities:
Year: 2022 PMID: 35126603 PMCID: PMC8813230 DOI: 10.1155/2022/6864195
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Pharmacological mechanism of moxibustion in the treatment of primary dysmenorrhea. PGE2, prostaglandin E2; PGF2α, prostaglandin F2α; P, progesterone; E2, estradiol; AVP, vasopressin; OT, oxytocin; β-EP, β-endorphin.
Overview of clinical studies of moxibustion.
| Intervention method | Number of patients with PD | Experiment method | Observation of efficacy | Result |
|---|---|---|---|---|
| The herb-partitioned moxibustion [ | 171 | Herb-partitioned moxibustion group (A) and starch-partitioned moxibustion group (B) were applied to shenque (CV8) (umbilical every menstrual cycle approximately 2∼3 times, until menstruating). Acupuncture group (C) was provided at sanyinjiao (SP6) (started acupuncture 3∼5 days before menstruation, once a day until menstruating). Three menstrual cycles are considered a course of treatment. | Clinical efficacy, E2, P, PGF2 | The cured rate in group A was better than those in groups B and C ( |
|
| ||||
| Heat-sensitive sensation and the conventional warm sensation of moxibustion [ | 189 | Heat-sensitive moxibustion and conventional warm sensation groups were applied to guanyuan (GV4) for 40 min beginning 5 days before menstruation. Each menstrual cycle was treated for (7 ± 2) days, and both groups were treated for three periods. | MPQ, CMSS | MPQ and CMSS scores were lower in the treatment group than the control group ( |
|
| ||||
| Ginger moxibustion combined with acupuncture and ibuprofen sustained-release capsules [ | 60 | The treatment group was treated with ginger moxibustion at shenque (RN8) cooperated with acupuncture at sanyinjiao (SP6), zusanli (ST36), hegu (LI4), and neiguan (PC6) once per day, starting 5 days before menstruation continued for 7 days in each menstrual cycle. The control group took orally two times/day when symptoms of dysmenorrhea occurred. Both groups were treated for three menstrual cycles. | Effective rate, VAS score, PGE2, PGF2 | The instant curative effect, recent curative effect, and long-term curative effect in the treatment group were better than those in the control groups ( |
|
| ||||
| Moxibustion [ | 147 | Moxibustion was applied for 20 min at guanyuan (GV4) once daily, seven times in total. Staring 5 days before menstruation, continued for 7 days for three consecutive menstrual cycles, followed up for three menstrual cycles. | The practical clinical rate, TCM symptoms, VAS score, CMSS score, persistent pain time, usage of painkillers, and QOL | The total effective rate was 44.89%, the total score of the symptoms, VAS score, CMSS score, pain persistent time, and usage rate of painkillers were reduced ( |
|
| ||||
| Thunder-fire moxibustion combined with wenjing zhitong decoction [ | 116 | The treatment group was treated with thunder-fire moxibustion combined with wenjing zhitong decoction once per day, starting 7 days before menstruation until the end of menstruation. The control group took orally two times/day. Both groups were treated for three menstrual cycles. | Clinical efficacy, TCM symptoms, VAS score | Clinical efficacy, TCM symptoms, and VAS score in the treatment group were better than those in control group ( |
|
| ||||
| Drug-spreading moxibustion and oral administration of meloxicam [ | 101 | Drug-spreading moxibustion was used on the lumbosacral acupoints area and then around the lower abdominal 5 days before menstruation until the third day of menstruation, once 3 days. Meloxicam was prescribed one day before menstruation 7.5 mg at a time once a day and continuously for 3 days. | Clinical efficacy, RI, and PI | The effective rate was 92.3% in the treatment group, which was better than that in the control group ( |
|
| ||||
| Thunder-fire moxibustion combined with ear points and ibuprofen sustained-release capsules [ | 76 | The thunder-fire moxibustion selected zhongwan (CV12), guanyuan (CV4), and double sides of zusanli (ST36) points, 30 min per point each time, once a day for 3 consecutive days. Auricular points are selected from the uterus, endocrine, shenmen (TF4), liver, and kidney. For 3 days, oral ibuprofen sustained-release capsules 0.3 g/time, once in the morning and in the evening. Both groups were treated for three menstrual cycles. | VAS score, CMSS score, PGF2 | The VAS scores and CMSS scores of the treatment group were reduced than those in the control group ( |
|
| ||||
| Herb-partitioned moxibustion at the umbilicus combined with abdominal acupuncture [ | 82 | The treatment group was intervened by herb-partitioned moxibustion at the umbilicus plus abdominal acupuncture, and the control group was treated with abdominal acupuncture alone, once per day, starting 7 days before menstruation for 3 consecutive days. | Clinical efficacy, PGE2, PGF2 | The clinical efficacy rate in the treatment group was higher than that in the control group ( |
|
| ||||
| Moxibustion combined with warm needling [ | 120 | In the control group, warm needling was used at guanyuan (CV4) and sanyinjiao (SP6). In the treatment group, besides the same treatment as the control group, moxibustion was added at shenque (CV8). The first menstrual cycle started one day before menstruation, whereas menstrual cycles 2, 3, and 4, started 3 days before menstruation, once a day for 3 days until menstruation. | The score of the severity and the score of the total frequency in the retrospective scale of dysmenorrhea symptoms, VAS score, and the safety of the two therapeutic methods. | The score of severity, score of total frequency, and VAS score of menstrual pain were all reduced, and the effect of the treatment group was better than that of the control group ( |
|
| ||||
| Baixiao moxibustion and ibuprofen sustained-release capsules [ | 202 | Patients in group A received baixiao moxibustion for 30 min; group B received baixiao moxibustion for 15 min; group C was prescribed with ibuprofen sustained-release capsules. Groups A and B were used at guanyuan (CV4), sanyinjiao (SP6), and mingmen (GV4), once per day, starting 10 days before menstruation for 7 consecutive days. Both groups were treated for three menstrual cycles. | The real-time, short-term, and long-term VAS score, RI, PI, PSV, EDV, and PGF2 | The treatment group's real-time, short-term, and long-term efficacy were better than those of the control group ( |
PGE2, prostaglandin E2; PGF2α, prostaglandin F2 α; P, progesterone; E2, estradiol; VAS, visual analog scale; CMSS, cox menstrual symptom scale; TCM symptoms, traditional Chinese medicine syndrome factors; MPQ, mcgill pain questionnaire; QOL, quality of life. Uterine-artery hemodynamic indexes: resistance index (RI), pulsatility index (PI), peak systolic velocity (PSV), end diastolic velocity (EDV).